All posts
-
Tough crushing made easier, Sandvik claims, with latest range
Brand-new jaw crusher variety from Sandvik .
-
Gilead Sciences and Kymera Therapeutics sign deal on potential cancer drug
The offer might total up to USD 750m.
-
Gubra shareholders only a formality away from lucrative payout
At the very same time, a financial investment economic expert thinks that Zealand Pharma, which has actually likewise offered a medicine prospect, can gain from a comparable effort…
-
Chemometec rises from downturn – further growth is in store
It’s difficult to locate various other clinical tool firms that are expanding as quick as Danish Chemometec is right currently, claims expert.
-
Eli Lilly gears up in India
Novo Nordisk introduced previously today that it has actually begun offering its fat burning medication Wegovy in India.
-
After harsh accusations: Novo Nordisk dodges questions of legal action against Hims & Hers
The Danish pharmaceutical firm introduced on Monday that it had actually ended its partnership with United States firm Hims & Hers after much less than 2 months.
-
RFK Jr. pledges support for the US biotech sector: “We do everything that we can to support that industry”
The United States Assistant of Health And Wellness and Person Providers has actually met reps from the United States biotech sector numerous times to go over FDA cuts.
-
Security advisor on Novo Nordisk in Iran: They are ready to evacuate very quickly
According to a Danish security advisor, Novo Nordisk has engaged several security companies in relation to the current conflict in the Middle East.
-
CEVA Logistics makes HVO100 biofuel available across UK network
The article CEVA Logistics makes HVO100 biofuel available across UK network showed up initially on Logistics Manager.
-
Microsoft kills the iconic Windows ‘Blue Screen of Death.’ It looks like this now
Almost every Windows user has encountered the legendary “Blue Screen of Death” (or BSOD for short) at least once. More than anything else, the infamous error screen is characterize…
